TY - JOUR
T1 - The dosimetric and temporal effects of respiratory-gated, high-dose-rate radiation therapy in patients with lung cancer
AU - Rouabhi, Ouided
AU - Gross, Brandie
AU - Bayouth, John
AU - Xia, Junyi
N1 - Publisher Copyright:
© The Author(s) 2018.
PY - 2019
Y1 - 2019
N2 - Purpose: To evaluate the dosimetric and temporal effects of high-dose-rate respiratory-gated radiation therapy in patients with lung cancer. Methods: Treatment plans from 5 patients with lung cancer (3 nongated and 2 gated at 80EX-80IN) were retrospectively evaluated. Prescription dose for these patients varied from 8 to 18 Gy/fraction with 3 to 5 treatment fractions. Using the same treatment planning criteria, 4 new treatment plans, corresponding to 4 gating windows (20EX-20IN, 40EX-40IN, 60EX-60IN, and 80EX-80IN), were generated for each patient. Mean tumor dose, mean lung dose, and lung V20 were used to assess the dosimetric effects. A MATLAB algorithm was developed to compute treatment time. Results: Mean lung dose and lung V20 were on average reduced between -16.1% to -6.0% and -20.0% to -7.2%, respectively, for gated plans when compared to the corresponding nongated plans, and between -5.8% to -4.2% and -7.0% to -5.4%, respectively, for plans with smaller gating windows when compared to the corresponding plans gated at 80EX-80IN. Treatment delivery times of gated plans using high-dose rate were reduced on average between -19.7% (-0.10 min/100 MU) and -27.2% (-0.13 min/100 MU) for original nongated plans and -15.6% (-0.15 min/100 MU) and -20.3% (-0.19 min/100 MU) for original 80EX-80IN-gated plans. Conclusion: Respiratory-gated radiation therapy in patients with lung cancer can reduce lung dose while maintaining tumor dose. Because treatment delivery during gated therapy is discontinuous, total treatment time may be prolonged. However, this increase in treatment time can be offset by increasing the dose delivery rate. Estimation of treatment time may be helpful in selecting patients for respiratory gating and choosing appropriate gating windows.
AB - Purpose: To evaluate the dosimetric and temporal effects of high-dose-rate respiratory-gated radiation therapy in patients with lung cancer. Methods: Treatment plans from 5 patients with lung cancer (3 nongated and 2 gated at 80EX-80IN) were retrospectively evaluated. Prescription dose for these patients varied from 8 to 18 Gy/fraction with 3 to 5 treatment fractions. Using the same treatment planning criteria, 4 new treatment plans, corresponding to 4 gating windows (20EX-20IN, 40EX-40IN, 60EX-60IN, and 80EX-80IN), were generated for each patient. Mean tumor dose, mean lung dose, and lung V20 were used to assess the dosimetric effects. A MATLAB algorithm was developed to compute treatment time. Results: Mean lung dose and lung V20 were on average reduced between -16.1% to -6.0% and -20.0% to -7.2%, respectively, for gated plans when compared to the corresponding nongated plans, and between -5.8% to -4.2% and -7.0% to -5.4%, respectively, for plans with smaller gating windows when compared to the corresponding plans gated at 80EX-80IN. Treatment delivery times of gated plans using high-dose rate were reduced on average between -19.7% (-0.10 min/100 MU) and -27.2% (-0.13 min/100 MU) for original nongated plans and -15.6% (-0.15 min/100 MU) and -20.3% (-0.19 min/100 MU) for original 80EX-80IN-gated plans. Conclusion: Respiratory-gated radiation therapy in patients with lung cancer can reduce lung dose while maintaining tumor dose. Because treatment delivery during gated therapy is discontinuous, total treatment time may be prolonged. However, this increase in treatment time can be offset by increasing the dose delivery rate. Estimation of treatment time may be helpful in selecting patients for respiratory gating and choosing appropriate gating windows.
KW - 4D dose
KW - 4DCT
KW - Gated radiation therapy
KW - Gating
KW - Treatment time
UR - http://www.scopus.com/inward/record.url?scp=85062178441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062178441&partnerID=8YFLogxK
U2 - 10.1177/1533033818816072
DO - 10.1177/1533033818816072
M3 - Article
C2 - 30803374
AN - SCOPUS:85062178441
SN - 1533-0346
VL - 18
JO - Technology in Cancer Research and Treatment
JF - Technology in Cancer Research and Treatment
ER -